These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11197990)

  • 41. Methylphenidate and chromosome damage.
    Jacobson-Kram D; Mattison D; Shelby M; Slikker W; Tice R; Witt K
    Cancer Lett; 2008 Feb; 260(1-2):216-8. PubMed ID: 18055105
    [No Abstract]   [Full Text] [Related]  

  • 42. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does my child need Ritalin? Stimulants are still the most effective treatment for ADHD. The challenge is to use them wisely.
    Adesman A
    Newsweek; 2000 Apr; 135(17):81. PubMed ID: 10848381
    [No Abstract]   [Full Text] [Related]  

  • 45. Preschool meds: the first clinical trial examining the effects of generic Ritalin on 3- to 5-year-old subjects raises questions not only about the safety of the drug but also about the ethics of testing on ever younger brains.
    Stolberg SG
    N Y Times Mag; 2002 Nov; ():58-61. PubMed ID: 17080573
    [No Abstract]   [Full Text] [Related]  

  • 46. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al.
    Preston RJ; Kollins SH; Swanson JM; Greenhill LL; Wigal T; Elliott GR; Vitiello B
    Cancer Lett; 2005 Dec; 230(2):292-4. PubMed ID: 16019134
    [No Abstract]   [Full Text] [Related]  

  • 47. [Attention deficit hyperactivity syndrome (ADHS) in Germany].
    Schlander M
    Krankenpfl J; 2004; 42(5-6):152. PubMed ID: 15527216
    [No Abstract]   [Full Text] [Related]  

  • 48. New Ritalin ad blitz makes parents jumpy.
    Novak V
    Time; 2001 Sep; 158(10):62-3. PubMed ID: 11558351
    [No Abstract]   [Full Text] [Related]  

  • 49. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nurse-delivered and doctor-delivered care in an attention deficit hyperactivity disorder follow-up clinic: a comparative study using propensity score matching.
    Foreman DM; Morton S
    J Adv Nurs; 2011 Jun; 67(6):1341-8. PubMed ID: 21375572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of withdrawal of Ritalin LA in the Western Cape.
    Donker Fv; Riordan G; Wilmshurst J
    S Afr Med J; 2008 Aug; 98(8):570. PubMed ID: 18928026
    [No Abstract]   [Full Text] [Related]  

  • 52. Response to comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al.
    El-Zein RA; Hay MJ; Lopez MS; Bondy ML; Morris DL; Legator MS; Abdel-Rahman SZ
    Cancer Lett; 2006 Jan; 231(1):146-8. PubMed ID: 16290920
    [No Abstract]   [Full Text] [Related]  

  • 53. Exploring clinician uncertainty in the diagnosis and treatment of attention deficit hyperactivity disorder.
    Rafalovich A
    Sociol Health Illn; 2005 Apr; 27(3):305-23. PubMed ID: 15953210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.
    Leonard BE; McCartan D; White J; King DJ
    Hum Psychopharmacol; 2004 Apr; 19(3):151-80. PubMed ID: 15079851
    [No Abstract]   [Full Text] [Related]  

  • 58. Attention deficit hyperactivity disorder.
    Morrell P
    Indian Pediatr; 1998 Oct; 35(10):953-8. PubMed ID: 10216717
    [No Abstract]   [Full Text] [Related]  

  • 59. Punding Under Methylphenidate Treatment in a Patient With Adult Attention-Deficit/Hyperactivity Disorder.
    Aydin Ö; Tanriöver E; Poyraz CA
    J Clin Psychopharmacol; 2020; 40(6):631-632. PubMed ID: 33136926
    [No Abstract]   [Full Text] [Related]  

  • 60. ADHD.
    Taylor E
    Am J Bioeth; 2005; 5(3):W17. PubMed ID: 16006370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.